Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina

Autores
Palacios, Alfredo; Espinola, Natalia; Gonzalez, Juan Martin; Rojas Roque, Carlos; Rivas, Maria Marta; Kanevski, Diego; Morisset, Pierre; Augustovski, Federico Ariel; Pichón-Riviere, Andres; Bardach, Ariel Esteban
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objective: This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.Methods: A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).Results: For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.Conclusion: The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.
Fil: Palacios, Alfredo. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino Unido
Fil: Espinola, Natalia. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Gonzalez, Juan Martin. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Rojas Roque, Carlos. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino Unido
Fil: Rivas, Maria Marta. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Kanevski, Diego. AbbVie Argentina; Argentina
Fil: Morisset, Pierre. AbbVie Argentina; Argentina
Fil: Augustovski, Federico Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Materia
Budget impact
Venetoclax
Chemotherapy
Argentina
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/265252
Acceder
id CONICETDig_aae18f1026623e03abeb601437cf97f5
oai_identifier_str oai:ri.conicet.gov.ar:11336/265252
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in ArgentinaPalacios, AlfredoEspinola, NataliaGonzalez, Juan MartinRojas Roque, CarlosRivas, Maria MartaKanevski, DiegoMorisset, PierreAugustovski, Federico ArielPichón-Riviere, AndresBardach, Ariel EstebanBudget impactVenetoclaxChemotherapyArgentinahttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Objective: This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.Methods: A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).Results: For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.Conclusion: The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.Fil: Palacios, Alfredo. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino UnidoFil: Espinola, Natalia. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Gonzalez, Juan Martin. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Rojas Roque, Carlos. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino UnidoFil: Rivas, Maria Marta. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Kanevski, Diego. AbbVie Argentina; ArgentinaFil: Morisset, Pierre. AbbVie Argentina; ArgentinaFil: Augustovski, Federico Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaPublic Library of Science2024-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/265252Palacios, Alfredo; Espinola, Natalia; Gonzalez, Juan Martin; Rojas Roque, Carlos; Rivas, Maria Marta; et al.; Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina; Public Library of Science; Plos One; 19; 1; 1-2024; 1-161932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0295798info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0295798info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:03:01Zoai:ri.conicet.gov.ar:11336/265252instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:03:02.157CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
title Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
spellingShingle Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
Palacios, Alfredo
Budget impact
Venetoclax
Chemotherapy
Argentina
title_short Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
title_full Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
title_fullStr Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
title_full_unstemmed Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
title_sort Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
dc.creator.none.fl_str_mv Palacios, Alfredo
Espinola, Natalia
Gonzalez, Juan Martin
Rojas Roque, Carlos
Rivas, Maria Marta
Kanevski, Diego
Morisset, Pierre
Augustovski, Federico Ariel
Pichón-Riviere, Andres
Bardach, Ariel Esteban
author Palacios, Alfredo
author_facet Palacios, Alfredo
Espinola, Natalia
Gonzalez, Juan Martin
Rojas Roque, Carlos
Rivas, Maria Marta
Kanevski, Diego
Morisset, Pierre
Augustovski, Federico Ariel
Pichón-Riviere, Andres
Bardach, Ariel Esteban
author_role author
author2 Espinola, Natalia
Gonzalez, Juan Martin
Rojas Roque, Carlos
Rivas, Maria Marta
Kanevski, Diego
Morisset, Pierre
Augustovski, Federico Ariel
Pichón-Riviere, Andres
Bardach, Ariel Esteban
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Budget impact
Venetoclax
Chemotherapy
Argentina
topic Budget impact
Venetoclax
Chemotherapy
Argentina
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objective: This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.Methods: A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).Results: For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.Conclusion: The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.
Fil: Palacios, Alfredo. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino Unido
Fil: Espinola, Natalia. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Gonzalez, Juan Martin. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Rojas Roque, Carlos. Instituto de Efectividad Clínica y Sanitaria; Argentina. University of York; Reino Unido
Fil: Rivas, Maria Marta. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Kanevski, Diego. AbbVie Argentina; Argentina
Fil: Morisset, Pierre. AbbVie Argentina; Argentina
Fil: Augustovski, Federico Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
description Objective: This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.Methods: A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).Results: For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.Conclusion: The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.
publishDate 2024
dc.date.none.fl_str_mv 2024-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/265252
Palacios, Alfredo; Espinola, Natalia; Gonzalez, Juan Martin; Rojas Roque, Carlos; Rivas, Maria Marta; et al.; Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina; Public Library of Science; Plos One; 19; 1; 1-2024; 1-16
1932-6203
CONICET Digital
CONICET
url http://hdl.handle.net/11336/265252
identifier_str_mv Palacios, Alfredo; Espinola, Natalia; Gonzalez, Juan Martin; Rojas Roque, Carlos; Rivas, Maria Marta; et al.; Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina; Public Library of Science; Plos One; 19; 1; 1-2024; 1-16
1932-6203
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0295798
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0295798
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613841580720128
score 13.070432

Publicaciones similares